Preprints.org

Weight Regain During Continued Incretin Therapy Is Associated With an Inflammatory Signature at Weight Nadir and Higher Cardiovascular Event Rates

At a glance

Of 58,618 adults with at least 5% initial weight loss and evaluable one-year trajectories, 8,389 (14.3%) regained at least five percentage points from their nadir. Regain was associated with inflammatory and acute-phase changes and higher cardiovascular and renal event rates, but the EHR could not verify drug ingestion or establish that regain caused those events.

The research question

How often does substantial weight regain occur after initial semaglutide or tirzepatide response, including when treatment remains documented, and what clinical signals accompany it?

Overview

Incretin withdrawal trials show that weight often returns after therapy stops, but routine-care rebound may also occur while treatment appears to continue. Investigators aligned each patient’s clinical history to their own lowest recorded weight, or nadir, to characterize documented treatment, laboratory changes, gastrointestinal and infectious diagnoses, and later clinical events surrounding weight regain after semaglutide or tirzepatide initiation.

Study design & methods

This retrospective cohort used de-identified EHR data from a federated U.S. network of more than 29 million patients. Adults initiating semaglutide or tirzepatide from 2021 through 2024 were required to have pre-index encounters and weights, no other incretin use in the prior year, no bariatric surgery, a further index-drug order within one year, and sufficient post-index weights. Among 58,618 patients who achieved at least 5% weight loss and had an evaluable one-year trajectory, regain was defined as at least five percentage points gained from the first-year nadir; 8,389 met that definition and 50,229 were sustained responders. Treatment documentation combined structured orders with NLP-extracted affirmative note mentions carried forward for 90 days. Laboratory and diagnosis patterns were aligned to the nadir, and time-varying event rates were adjusted for follow-up interval, brand, and age with Benjamini–Hochberg correction.

Regained weight tracked inflammatory changes and higher cardiovascular event rates

Weight regain occurred in 8,389 of 58,618 patients (14.3%). Among regain patients with at least 90 post-nadir days, 45.8% remained documented on treatment for at least half of follow-up at a dose maintained at or above their pre-nadir maximum, compared with 51.6% of sustained responders. At the nadir, regain patients had larger increases in neutrophil-to-lymphocyte ratio (+0.73 versus +0.29) and neutrophils (+0.48 versus +0.12 ×10⁹/L), lower albumin change (−0.12 versus −0.03 g/dL), and falling rather than rising HDL (−0.65 versus +1.03 mg/dL; all P less than 0.001). During regained versus maintained-loss time, adjusted rates were higher for nonfatal major adverse cardiovascular events (12.9 versus 9.6 per 1,000 person-years; RR 1.43, 95% CI 1.22–1.67), heart-failure hospitalization (20.1 versus 13.6; RR 1.66, 1.45–1.89), and cardiac arrest (1.8 versus 0.9; RR 2.11, 1.37–3.26; all q less than 0.001).

Limitations & interpretation

These results support weight nadir as a potentially useful clinical transition point but do not show that continued medication exposure failed or that regain caused later cardiovascular events. Prescriptions and note mentions do not confirm dispensing or ingestion, and blinded physician review confirmed ongoing use in only 17 of 25 adjudicable patients categorized as maintained treatment. The regain and sustained-response groups differed at baseline; illness, medication pauses, reverse causation, visit frequency, selective laboratory testing, incomplete external prescribing data, and the first-year nadir definition could influence the findings. Generalizability is limited to patients with sufficiently dense EHR follow-up. Prospective studies with objective exposure measurement are needed. Evidence confidence: Moderate. Rationale: a large longitudinal cohort and consistent signals support the associations, but treatment exposure, residual confounding, and reverse causation remain unresolved. Confidence variables: design—retrospective observational; sample size—large; exposure—documented, not verified; generalizability—care-engaged U.S. patients.

Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.

Keep exploring.

All publications
CardiometabolismPreprint - Submitted for Peer-Review

Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss

While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

Preprints.org
October 21, 2026
CardiometabolismConference

Menopause Hormone Therapy and Weight Loss Response to GLP-1–Based Therapies in Midlife Women: A Retrospective Cohort Study

In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.

The Menopause Society — 2026 Annual Meeting
October 20, 2026
Your next question could change everything.

What will you
discover next?

Let’s find out
Ideas are connected. Your next discovery starts here.